GlassScriptPhysician profile
Caitlin Krieger
NPI 1558764548
$5,827.36
in general payments reported to CMS, 2019-2025
28 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $504 · 2022: $909 · 2023: $1,143 · 2024: $1,376 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,413.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,466.69 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $797.09 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $455.11 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $443.51 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $405.43 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $384.41 | 2022-2025 | Ibsrela |
| Pfizer INC. | $311.54 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $276.76 | 2024-2025 | Voquezna |
| Vivus LLC | $207.84 | 2021-2025 | Qsymia, Pancreaze |
| Madrigal Pharmaceuticals | $199.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $183.41 | 2024-2025 | |
| Celgene Corporation | $117.18 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $67.90 | 2021 | |
| Aimmune Therapeutics, INC. | $63.42 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $55.02 | 2024-2025 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.15 | 2023-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $48.01 | 2025 | Iqirvo |
| Lilly USA, LLC | $44.24 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $36.18 | 2022-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $31.69 | 2021-2022 | |
| Evoke Pharma, INC. | $28.93 | 2022 | |
| Organon LLC | $27.48 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.68 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $23.50 | 2021 | |
| Braintree Laboratories, INC. | $20.93 | 2021 | |
| Ethicon US, LLC | $20.26 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.59 | 2022 | |
| Fresenius Kabi USA, LLC | $15.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Krieger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.